-
Je něco špatně v tomto záznamu ?
De novo developed protein binders mimicking Interferon lambda signaling
L. Kolářová, J. Zahradník, M. Huličiak, P. Mikulecký, Y. Peleg, M. Shemesh, G. Schreiber, B. Schneider
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 2005 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2005-01-01 do Před 1 rokem
Wiley Free Content
od 2005
PubMed
34826176
DOI
10.1111/febs.16300
Knihovny.cz E-zdroje
- MeSH
- antivirové látky metabolismus MeSH
- cytokiny metabolismus MeSH
- interferony * metabolismus MeSH
- interleukiny * metabolismus MeSH
- lidé MeSH
- signální transdukce MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
We hereby describe the process of design and selection of nonantibody protein binders mimicking cytokine signaling. We chose to mimic signaling of IFN-λ1, type 3 interferon (also known as IL-29) for its novelty and the importance of its biological functions. All four known interferons λ signal through binding to the extracellular domains of IL-28 receptor 1 (IL-28R1) and IL-10 receptor 2 (IL-10R2). Our binders were therefore trained to bind both receptors simultaneously. The bifunctional binder molecules were developed by yeast display, a method of directed evolution. The signaling capacity of the bivalent binders was tested by measuring phosphorylation of the JAK/STAT signaling pathway and production of mRNA of six selected genes naturally induced by IFN- λ1 in human cell lines. The newly developed bivalent binders offer opportunities to study cytokine-related biological functions and modulation of the cell behavior by receptor activation on the cell surfaces alternative to the use of natural IFN-λ.
Department of Biomolecular Sciences Weizmann Institute of Science Rehovot Israel
Institute of Biotechnology of the Czech Academy of Sciences BIOCEV Vestec Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018559
- 003
- CZ-PrNML
- 005
- 20220804134847.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/febs.16300 $2 doi
- 035 __
- $a (PubMed)34826176
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kolářová, Lucie $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic
- 245 10
- $a De novo developed protein binders mimicking Interferon lambda signaling / $c L. Kolářová, J. Zahradník, M. Huličiak, P. Mikulecký, Y. Peleg, M. Shemesh, G. Schreiber, B. Schneider
- 520 9_
- $a We hereby describe the process of design and selection of nonantibody protein binders mimicking cytokine signaling. We chose to mimic signaling of IFN-λ1, type 3 interferon (also known as IL-29) for its novelty and the importance of its biological functions. All four known interferons λ signal through binding to the extracellular domains of IL-28 receptor 1 (IL-28R1) and IL-10 receptor 2 (IL-10R2). Our binders were therefore trained to bind both receptors simultaneously. The bifunctional binder molecules were developed by yeast display, a method of directed evolution. The signaling capacity of the bivalent binders was tested by measuring phosphorylation of the JAK/STAT signaling pathway and production of mRNA of six selected genes naturally induced by IFN- λ1 in human cell lines. The newly developed bivalent binders offer opportunities to study cytokine-related biological functions and modulation of the cell behavior by receptor activation on the cell surfaces alternative to the use of natural IFN-λ.
- 650 _2
- $a antivirové látky $x metabolismus $7 D000998
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a interferony $x metabolismus $7 D007372
- 650 12
- $a interleukiny $x metabolismus $7 D007378
- 650 _2
- $a signální transdukce $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zahradník, Jiří $u Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel $1 https://orcid.org/0000000286984236
- 700 1_
- $a Huličiak, Maroš $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic
- 700 1_
- $a Mikulecký, Pavel $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic $1 https://orcid.org/0000000328380335
- 700 1_
- $a Peleg, Yoav $u Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel
- 700 1_
- $a Shemesh, Maya $u Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel
- 700 1_
- $a Schreiber, Gideon $u Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel $1 https://orcid.org/0000000229225882
- 700 1_
- $a Schneider, Bohdan $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic $1 https://orcid.org/0000000178553690
- 773 0_
- $w MED00008414 $t The FEBS journal $x 1742-4658 $g Roč. 289, č. 9 (2022), s. 2672-2684
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34826176 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134841 $b ABA008
- 999 __
- $a ok $b bmc $g 1822249 $s 1169802
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 289 $c 9 $d 2672-2684 $e 20211207 $i 1742-4658 $m The FEBS journal $n FEBS J $x MED00008414
- LZP __
- $a Pubmed-20220720